NextCure, Inc. (NXTC)
2025-06-30 | ||||
|---|---|---|---|---|
| Unrealized (loss) gain on marketable securities | -7 | |||
| Other income, net | 484 | |||
| Research and development | 24,091 | |||
| General and administrative | 3,201 | |||
| Total operating expenses | 27,292 | |||
| Loss from operations | -27,292 | |||
| Net loss | -26,808 | |||
| Total comprehensive loss | -26,815 | |||
| Earnings per share, basic | -11.29 | |||
| Earnings per share, diluted | -11.29 | |||
| Weighted average number of shares outstanding, basic | 2,374,729 | |||
| Weighted average number of shares outstanding, diluted | 2,374,729 | |||